CL2024002389A1 - Uso del agonista del receptor de melanocortina 4 para prevenir o tratar una enfermedad genética - Google Patents
Uso del agonista del receptor de melanocortina 4 para prevenir o tratar una enfermedad genéticaInfo
- Publication number
- CL2024002389A1 CL2024002389A1 CL2024002389A CL2024002389A CL2024002389A1 CL 2024002389 A1 CL2024002389 A1 CL 2024002389A1 CL 2024002389 A CL2024002389 A CL 2024002389A CL 2024002389 A CL2024002389 A CL 2024002389A CL 2024002389 A1 CL2024002389 A1 CL 2024002389A1
- Authority
- CL
- Chile
- Prior art keywords
- melanocortin
- treat
- prevent
- receptor agonist
- genetic disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20220016377 | 2022-02-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024002389A1 true CL2024002389A1 (es) | 2025-01-31 |
Family
ID=87564659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024002389A CL2024002389A1 (es) | 2022-02-08 | 2024-08-08 | Uso del agonista del receptor de melanocortina 4 para prevenir o tratar una enfermedad genética |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250134898A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4461297A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025505229A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230120106A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119300835A (cg-RX-API-DMAC7.html) |
| AR (1) | AR128463A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023218785A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3248118A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024002389A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2024011882A2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024009854A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI838114B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023153762A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3202315A1 (en) * | 2020-12-22 | 2022-06-30 | Hee Dong Park | Use as selective agonist of malanocortin-4 receptor |
| KR20250046623A (ko) * | 2023-09-27 | 2025-04-03 | 주식회사 엘지화학 | 멜라노코르틴-4 수용체 효능제의 pcsk1 결핍 적응증과 연관된 희귀성 유전적 비만질환의 예방 또는 치료 용도 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI332501B (en) * | 2006-07-14 | 2010-11-01 | Lg Life Sciences Ltd | Melanocortin receptor agonists |
| US12516047B2 (en) * | 2019-11-07 | 2026-01-06 | Lg Chem, Ltd. | Melanocortin-4 receptor agonists |
| CN116507615A (zh) * | 2020-10-29 | 2023-07-28 | 株式会社Lg化学 | 黑皮质素受体激动剂化合物的晶型i及其制备方法 |
| TWI804170B (zh) * | 2021-01-21 | 2023-06-01 | 南韓商Lg化學股份有限公司 | 黑皮質素-4受體促效劑的用途 |
| TWI826938B (zh) * | 2021-02-26 | 2023-12-21 | 南韓商Lg化學股份有限公司 | 黑皮質素-4受體促效劑 |
| TWI861780B (zh) * | 2022-03-28 | 2024-11-11 | 南韓商Lg化學股份有限公司 | 預防或治療肥胖的聯合療法 |
-
2023
- 2023-02-06 TW TW112104117A patent/TWI838114B/zh active
- 2023-02-07 US US18/837,125 patent/US20250134898A1/en active Pending
- 2023-02-07 EP EP23753110.8A patent/EP4461297A4/en active Pending
- 2023-02-07 CN CN202380032193.6A patent/CN119300835A/zh active Pending
- 2023-02-07 CA CA3248118A patent/CA3248118A1/en active Pending
- 2023-02-07 JP JP2024547302A patent/JP2025505229A/ja active Pending
- 2023-02-07 KR KR1020230016160A patent/KR20230120106A/ko not_active Ceased
- 2023-02-07 AR ARP230100283A patent/AR128463A1/es unknown
- 2023-02-07 AU AU2023218785A patent/AU2023218785A1/en active Pending
- 2023-02-07 WO PCT/KR2023/001712 patent/WO2023153762A1/ko not_active Ceased
-
2024
- 2024-08-08 CL CL2024002389A patent/CL2024002389A1/es unknown
- 2024-08-12 MX MX2024009854A patent/MX2024009854A/es unknown
- 2024-08-30 CO CONC2024/0011882A patent/CO2024011882A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025505229A (ja) | 2025-02-21 |
| AU2023218785A1 (en) | 2024-08-22 |
| CA3248118A1 (en) | 2025-01-24 |
| WO2023153762A1 (ko) | 2023-08-17 |
| EP4461297A4 (en) | 2025-04-09 |
| TW202339761A (zh) | 2023-10-16 |
| CN119300835A (zh) | 2025-01-10 |
| AR128463A1 (es) | 2024-05-08 |
| CO2024011882A2 (es) | 2025-01-23 |
| TWI838114B (zh) | 2024-04-01 |
| EP4461297A1 (en) | 2024-11-13 |
| US20250134898A1 (en) | 2025-05-01 |
| KR20230120106A (ko) | 2023-08-16 |
| MX2024009854A (es) | 2024-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024011882A2 (es) | Uso del agonista del receptor de melanocortina 4 para prevenir o tratar una enfermedad genética rara de la obesidad | |
| ECSP22092977A (es) | Antagonista del receptor crf1 para el tratamiento de la hiperplasia suprarrenal congénita | |
| MX2021005011A (es) | Métodos de tratamiento del cáncer en pacientes identificados por biomarcadores con inhibidores no covalentes de cinasa 7 dependiente de ciclina (cdk7). | |
| JOP20220056A1 (ar) | مركبات rip1 تثبيطية وطرق عملها واستخدامها | |
| MX388748B (es) | Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak. | |
| MX2023008098A (es) | Uso de agonista del receptor de melanocortina-4. | |
| ECSP099371A (es) | INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA | |
| MXPA04002537A (es) | Alquinos como inhibidores de metaloproteinasa de matriz. | |
| AR083957A1 (es) | Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica | |
| SV2007002146A (es) | Difenilimidazopirimidina e imidazol aminas como inhibidores de beta-secretasa ref. am101727 | |
| AR109590A2 (es) | Régimen posológico para inhibidores de comt | |
| AU2025283528A1 (en) | Methods of treating WHSC1-overexpressing cancers by inhibiting SETD2 | |
| ECSP10010034A (es) | 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos | |
| GT200500158A (es) | Derivados de amino-5,5-difenilimidazolona para la inhibicion de la b-secretasa | |
| ECSP055525A (es) | Inhibidores de cinasas de tirosina | |
| PA8601001A1 (es) | Fenacilo 2-hidroxi-3-diaminoalcanos | |
| CU20080027A7 (es) | Bencimidazoles sustituidos como inhibidores de cinasa | |
| CL2008001238A1 (es) | Anticuerpo antagonista aislado anti-receptor grig/pro362/jam4/stigma murino con numero de deposito atcc pat-8298; composicion farmaceutica; uso medico para inhibir la entrada celulst dependiente del complemento mediada por crig de un patogeno intracelular (pi), o para prevenir o tratar una enfermedadad infeccionsa mediada por un pi | |
| CY1108292T1 (el) | Αντικαρκινικο σκευασμα που περιεχει dmxaa | |
| MX2009001660A (es) | Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriasis. | |
| CO2024000221A2 (es) | Pirimidinil-pirazoles sustituidos como inhibidores de cdk2 | |
| ECSP055745A (es) | Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona | |
| PY1978496A (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| DE602006010834D1 (de) | Neue thiophensulfoximine zur behandlung von komplementvermittelten krankheiten und leiden | |
| MX2024008450A (es) | Piperidinil-metil-purina aminas enriquecidas con deuterio y compuestos relacionados y su uso en el tratamiento de enfermedades y condiciones |